Tien Liang BioTech Co., Ltd.
Tien Liang BioTech Co., Ltd. manufactures and sells pharmaceutical products in Taiwan. The company offers Chinese medicine products, such as pills for liver and kidney deficiency, lower back pain and sore feet, dizziness and blurred vision, thirst, dry tongue and sore throat, and heel pain, as well as rheumatic pain, joint pain, generalized pain, wind-cold-dampness arthralgia, gout, neuralgia, be… Read more
Market Cap & Net Worth: Tien Liang BioTech Co., Ltd. (4127)
Tien Liang BioTech Co., Ltd. (TWO:4127) has a market capitalization of $49.10 Million (NT$1.62 Billion) as of March 19, 2026. Listed on the TWO stock exchange, this Taiwan-based company holds position #24972 globally and #1536 in its home market, demonstrating a -1.80% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Tien Liang BioTech Co., Ltd.'s stock price NT$35.50 by its total outstanding shares 45760000 (45.76 Million).
Tien Liang BioTech Co., Ltd. Market Cap History: 2025 to 2026
Tien Liang BioTech Co., Ltd.'s market capitalization history from 2025 to 2026. Data shows growth from $42.87 Million to $49.10 Million (0.00% CAGR).
Tien Liang BioTech Co., Ltd. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Tien Liang BioTech Co., Ltd.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 4127 by Market Capitalization
Companies near Tien Liang BioTech Co., Ltd. in the global market cap rankings as of March 19, 2026.
Key companies related to Tien Liang BioTech Co., Ltd. by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #422 globally with a market cap of $51.61 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #432 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #452 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #719 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #422 | Zoetis Inc | NYSE:ZTS | $51.61 Billion | $117.35 |
| #432 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.31 |
| #452 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #719 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Tien Liang BioTech Co., Ltd. Historical Marketcap From 2025 to 2026
Between 2025 and today, Tien Liang BioTech Co., Ltd.'s market cap moved from $42.87 Million to $ 49.10 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$49.10 Million | +14.52% |
| 2025 | NT$42.87 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of Tien Liang BioTech Co., Ltd. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $49.10 Million USD |
| MoneyControl | $49.10 Million USD |
| MarketWatch | $49.10 Million USD |
| marketcap.company | $49.10 Million USD |
| Reuters | $49.10 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.